Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT

Phytomedicine. 2023 Apr:112:154687. doi: 10.1016/j.phymed.2023.154687. Epub 2023 Jan 29.

Abstract

Background: Hepatocellular carcinoma has high ability of vascular invasion and metastasis. Vasculogenic mimicry (VM) is closely related to the metastasis and recurrence of hepatocellular carcinoma (HCC). According to previous research, Chloranthus henryi has anti-tumor effect, but its molecular mechanism in the treatment of HCC has not yet been stated.

Purpose: In our study, we aimed to investigate the effect of the extract of Chloranthus henryi in HCC and its target and molecular mechanism. We hoped to explore potential drugs for HCC treatment.

Study design/methods: In this study, we isolated a chalcone compound from Chloranthus henryi, compound 4, identified as flavokawain A (FKA). We determined the anti-HCC effect of FKA by MTT and identified the target of FKA by molecular docking and CETSA. Hepatoma cells proliferation, migration, invasion, and VM formation were examined using EDU, wound healing, transwell, vasculogenic mimicry, and IF. WB, RT-PCR, and cell transfection were used to explore the mechanism of FKA on hepatoma cells. Tissue section staining is mainly used to demonstrate the effect of FKA on HCC in vivo.

Results: We confirmed that FKA can directly interact with CXCL12 and HCC proliferation, migration, invasion, and VM formation were all inhibited through reversing the EMT progress in vitro and in vivo through the PI3K/Akt/NF-κB signaling pathway. Additionally, by overexpressing and knocking down CXCL12, we got the same results.

Conclusion: FKA attenuated proliferation, invasion and metastatic and reversed EMT in HCC via PI3K/Akt/HIF-1α/NF-κB/Twist1 pathway by targeting CXCL12. This study proposed that FKA may be a candidate drug and prospective strategy for HCC therapy.

Keywords: CXCL12; EMT; Flavokawain A; HCC; Vasculogenic mimicry.

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Cell Line, Tumor
  • Cell Movement
  • Chemokine CXCL12
  • Epithelial-Mesenchymal Transition
  • Humans
  • Liver Neoplasms* / pathology
  • Molecular Docking Simulation
  • NF-kappa B
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt

Substances

  • Proto-Oncogene Proteins c-akt
  • NF-kappa B
  • flavokawain A
  • Phosphatidylinositol 3-Kinases
  • CXCL12 protein, human
  • Chemokine CXCL12